Popular on eTradeWire
- Rising Southeastern Rap Star V3ndetta00 Kicks Off 2025 with Electrifying Single "Push" - 302
- EZsolutions and Savify Partner to Deliver AI-Powered Online and Digital Solutions to Over 500,000 U.S. Businesses - 271
- Columbus Wizards Secure Thrilling 113-112 Victory in Final Home Game of the Season - 221
- Discover the latest trends and fashion - 206
- K9 Technology President Files a Lawsuit Against Google LLC - 192
- We all march for different reasons, but we march for the same cause - 182
- Paris Hilton, Congress Praised for Teen Behavioral Treatment Abuse Prevention - 168
- BK Adventure Celebrates 10 Years of Glow: Join the Year-Long Celebration! - 156
- NCYS Names Distinguished Sports Leaders to Officer Positions for 2025 - 153
- Uriel Medrano Joins RE1 Advisor as Property Manager/Realtor - 140
Similar on eTradeWire
- Enter the Dragon - PermianMuseum.com adds a Winged Dragon Fossil
- List2u Transforms Wound Care with Innovative Graft Solutions
- YourEggs Takes the Lead and Breaks Barriers with the World's Largest Fresh Egg Donor Database
- Kaplan Morrell Attorney Ronda Cordova Recognized in The Best Lawyers in America® for Workers' Compensation Law – Claimants
- ROC Sets a New Standard in Orthopedic Care with Innovations and Patient-Centered Growth in 2025
- Experience Dentistry Differently: VR for Pain-Free Visits
- Will we see you at ViVE 2025? Countdown to ViVE 2025: Join us on this exciting journey!
- Alliance Homecare Appoints Amy Romero as CMO to Drive Growth of TrustHouse, Private In-Home Nursing and Concierge Care
- OneSolution® Dental Implant Centers Celebrates Over 15,000 Successful Full-Arch Cases
- Gastroenterology Expert Dr. David L. Diehl Joins Actuated Medical's Medical Advisory Board
IVIEW Therapeutics Inc. Announces Dosing of First Patient in Phase 1/2 Clinical Trial of IVW-1001 for Dry Eye Disease
eTradeWire News/10774080
IVIEW Therapeutics Inc., a clinical stage biotechnology company advancing innovative treatments for ocular diseases, proudly announces the dosing of the first patient in the Phase 1/2 clinical trial of IVW-1001 Ophthalmic Eyelid Wipe. This milestone marks the initiation of the clinical evaluation of IVW-1001, a novel TRPM8 agonist designed to treat signs and symptoms of dry eye disease.
CRANBURY, N.J. - eTradeWire -- The commencement of patient dosing in the Phase 1/2 trial represents a significant advancement in IVIEW Therapeutics' mission to develop innovative solutions for individuals suffering from dry eye disease, particularly those inadequately managed by artificial tears. This first-in-human (FIH) trial aims to rigorously assess the safety, tolerability, and preliminary efficacy of IVW-1001.
Dry eye disease is a prevalent and burdensome condition affecting millions worldwide. IVW-1001, developed by IVIEW Therapeutics, offers promising potential as a therapeutic intervention through its TRPM8 agonist mechanism, targeting the underlying causes of dry eye. The innovative delivery route via an ophthalmic eyelid wipe further distinguishes IVW-1001 as a potentially groundbreaking treatment.
More on eTradeWire News
Houman Hemmati, MD, PhD, Chief Medical Advisor, leading the clinical development of the IVW-1001 program, stated, "Dosing the first patient in our Phase 1/2 clinical trial is an exciting and critical step forward. Our focus remains on thoroughly evaluating the safety and potential efficacy of IVW-1001. This investigational TRPM8 agonist offers an innovative approach to treating dry eye diseases, and we are committed to advancing this program to address the unmet needs of patients worldwide."
Bo Liang, PhD, MBA, Co-founder, Chairman, and CEO of IVIEW Therapeutics Inc., added, "We are thrilled to initiate the clinical development of IVW-1001 with the dosing of our first patient. This milestone underscores our commitment to pioneering treatments for dry eye diseases and highlights the potential of our novel TRPM8 activation mechanism. We look forward to the progress of this trial and the insights it will provide."
About IVIEW Therapeutics Inc.
More on eTradeWire News
IVIEW Therapeutics Inc. is a clinical stage biotechnology company focusing on innovative ophthalmic therapeutics. We are driven by the pursuit of innovative science that leads to differentiated products to fulfill unmet medical needs. We invest in novel mechanisms of action, and differentiated drug delivery technology platforms that allow us to bring forward assets with potentially superior target product profiles. The company's innovative portfolio of small molecules and gene therapy assets cover dry eye, myopia, conjunctivitis, glaucoma, and presbyopia. IVIEW is located in Cranbury, New Jersey with 11,045 sq. ft. laboratory and office space in the Princeton area. For additional information, please visit the Company's website at www.iviewtherapeutics.com. For further inquiries or media contacts, please reach out to our team at info@iviewinc.com
Dry eye disease is a prevalent and burdensome condition affecting millions worldwide. IVW-1001, developed by IVIEW Therapeutics, offers promising potential as a therapeutic intervention through its TRPM8 agonist mechanism, targeting the underlying causes of dry eye. The innovative delivery route via an ophthalmic eyelid wipe further distinguishes IVW-1001 as a potentially groundbreaking treatment.
More on eTradeWire News
- Osner's FC Gears Up for Highly Anticipated Match Against Barcelona Sporting Club
- AetherX's AETX Token in Alignment with Eric Trump's Vision for U.S.-Based Financial Leadership
- SUN & STARS INT'L FILM FESTIVAL Presents Two Award-Worthy Films From Ireland
- XRide Prioritises Sustainability with Electric Vehicles, Partners with TripAdvisor and Get Your Guide for UK Airport Transfers and Tour Rides
- Grasshopper Signup Launches to Rescue the World from Clunky, Ad-Filled, Overpriced Signup Forms
Houman Hemmati, MD, PhD, Chief Medical Advisor, leading the clinical development of the IVW-1001 program, stated, "Dosing the first patient in our Phase 1/2 clinical trial is an exciting and critical step forward. Our focus remains on thoroughly evaluating the safety and potential efficacy of IVW-1001. This investigational TRPM8 agonist offers an innovative approach to treating dry eye diseases, and we are committed to advancing this program to address the unmet needs of patients worldwide."
Bo Liang, PhD, MBA, Co-founder, Chairman, and CEO of IVIEW Therapeutics Inc., added, "We are thrilled to initiate the clinical development of IVW-1001 with the dosing of our first patient. This milestone underscores our commitment to pioneering treatments for dry eye diseases and highlights the potential of our novel TRPM8 activation mechanism. We look forward to the progress of this trial and the insights it will provide."
About IVIEW Therapeutics Inc.
More on eTradeWire News
- Martin Family Chiropractic Centers - Concord: Redefining Chiropractic Care in Concord, CA
- Luxury Living Meets Affordable Prices in South Carolina
- Moler's Audio Visual Brings Legacy Media into the Digital Age in Wichita, Kansas
- New SecuritySystemFinder.com Launches to Simplify Security System Selection for Homes and Businesses
- MEDIA ADVISORY: Leaders Across Georgia Gather in Atlanta for Georgia Municipal Association's Cities United Summit
IVIEW Therapeutics Inc. is a clinical stage biotechnology company focusing on innovative ophthalmic therapeutics. We are driven by the pursuit of innovative science that leads to differentiated products to fulfill unmet medical needs. We invest in novel mechanisms of action, and differentiated drug delivery technology platforms that allow us to bring forward assets with potentially superior target product profiles. The company's innovative portfolio of small molecules and gene therapy assets cover dry eye, myopia, conjunctivitis, glaucoma, and presbyopia. IVIEW is located in Cranbury, New Jersey with 11,045 sq. ft. laboratory and office space in the Princeton area. For additional information, please visit the Company's website at www.iviewtherapeutics.com. For further inquiries or media contacts, please reach out to our team at info@iviewinc.com
Source: IVIEW Therapeutics Inc.
0 Comments
Latest on eTradeWire News
- Power of Trendy Blends Vitamin C Serum: Your Skincare Solution for Anti-Aging
- YourEggs Takes the Lead and Breaks Barriers with the World's Largest Fresh Egg Donor Database
- Melbourne Aircon Specialist Announces Australian Day Deals on Air Conditioning
- Melbourne Aircon Specialist: Your Go-To Experts for Mitsubishi Electric 10.0kW Ducted System
- Greater Englewood Chamber of Commerce Launches 2025 Basic Financials for Business Program
- Climate Green Announces Exciting Australian Day Offers on Aircon and Heat Pump Installations
- EFLOW FX Launches AI Trading Algorithm Delivering 0.8%–2% Daily Returns
- Tyron Woodley First of 120 Elite MMA Athletes Selected in Inaugural Global Fight League Draft
- Talentflix cresce com modelo de assinatura e desafia recrutamento desumanizado no Brasil
- McKee Botanical Garden in Vero Beach is Awarded Prestigious Jean & John Greene Prize
- Mounts Botanical Garden's Winter Plant-a-Palooza – A Plant Sale & So Much More, February 8-9
- "Hey Ladies" Film Screening and Talkback Captivates Audience at CUNY
- Test Squared Launches Platform to Connect online Sellers with Verified Product Testers
- Expert Blog Series on Safety, Technology, and Choosing the Right Electrician
- Global Hair 4U, LLC Is Open For Business
- Introducing Global Hair 4U, LLC
- Unity Locale - West Dallas by CivilizedX: A Celebration of Culture, Creativity, and Community
- The Power of Free Trials in SaaS | freetrials.com
- A Touch of Class Tree Service: Arvada, CO Family-Run Business Boasts Nearly 30 Years of Experience
- RISO To Exhibit At Hunkeler Innovationdays 2025